{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:34:20Z","timestamp":1791041660427,"version":"4.1.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2024.27219","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:49:59Z","timestamp":1726242599000},"page":"e2427219","source":"Crossref","is-referenced-by-count":2,"title":["Tafamidis and the Paradox of Rare Disease Therapies"],"prefix":"10.1001","volume":"7","author":[{"given":"S\u00e9rgio Renato da R.","family":"Decker","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Internal Medicine Service, Moinhos de Vento Hospital, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"15","key":"zic240153r1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy.","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"zic240153r2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zic240153r3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"zic240153r4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26086","article-title":"National and regional Medicare spending on tafamidis, 2019-2021.","volume":"7","author":"Blatt","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zic240153r5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2023.02.002","article-title":"Out-of-pocket drug costs for Medicare beneficiaries with cardiovascular risk factors under the Inflation Reduction Act.","volume":"81","author":"Narasimmaraj","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"zic240153r6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.jacc.2023.03.414","article-title":"The Inflation Reduction Act and out-of-pocket drug costs for Medicare beneficiaries with cardiovascular disease.","volume":"81","author":"Kazi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"zic240153r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14211","article-title":"Cost-related medication nonadherence and desire for medication cost information among adults aged 65 years and older in the US in 2022.","volume":"6","author":"Dusetzina","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zic240153r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010057","article-title":"Exorbitant drug costs lead to inhumane consequences.","volume":"16","author":"Cassano","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"zic240153r9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010142","article-title":"Economic and ethical case for eliminating patient out-of-pocket costs.","volume":"16","author":"Liu","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"zic240153r10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamacardio.2020.0863","article-title":"Initial monthly cost of tafamidis-the real price for patients.","volume":"5","author":"Cuddy","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823651\/decker_2024_ic_240153_1725563913.56604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:11:40Z","timestamp":1732763500000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27219","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}